NEW YORK (GenomeWeb) – In an effort to cut down on unintended consequences of CRISPR/Cas9 gene editing, scientists from Harvard Medical School have combined two strategies known to reduce off-target enzyme activity.

Led by Nicolas Wyvekens and Shengdar Tsai, the researchers looked at the effects of combining dimerizing RNA-guided Fok1-dCas9 fusion nucleases (RFNs) with truncated guide RNAs (tru-RNAs). They published their results yesterday in Human Gene Therapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.